Immune Response BioPharma, Inc. - Product Pipeline Review - 2015

Published: Dec, 2015 | Pages: 42 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Immune Response BioPharma, Inc. - Product Pipeline Review - 2015

Summary

Global Markets Direct's, 'Immune Response BioPharma, Inc. - Product Pipeline Review - 2015', provides an overview of the Immune Response BioPharma, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Immune Response BioPharma, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Immune Response BioPharma, Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Immune Response BioPharma, Inc.'s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Immune Response BioPharma, Inc.'s pipeline products

Reasons to buy

- Evaluate Immune Response BioPharma, Inc.'s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Immune Response BioPharma, Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Immune Response BioPharma, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Immune Response BioPharma, Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Immune Response BioPharma, Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Explore the dormant and discontinued projects of Immune Response BioPharma, Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
Immune Response BioPharma, Inc. Snapshot 6
Immune Response BioPharma, Inc. Overview 6
Key Information 6
Key Facts 6
Immune Response BioPharma, Inc. - Research and Development Overview 7
Key Therapeutic Areas 7
Immune Response BioPharma, Inc. - Pipeline Review 10
Pipeline Products by Stage of Development 10
Pipeline Products - Monotherapy 11
Immune Response BioPharma, Inc. - Pipeline Products Glance 12
Immune Response BioPharma, Inc. - Late Stage Pipeline Products 12
Pre-Registration Products/Combination Treatment Modalities 12
Immune Response BioPharma, Inc. - Clinical Stage Pipeline Products 13
Phase II Products/Combination Treatment Modalities 13
Phase I Products/Combination Treatment Modalities 14
Immune Response BioPharma, Inc. - Early Stage Pipeline Products 15
Preclinical Products/Combination Treatment Modalities 15
Immune Response BioPharma, Inc. - Drug Profiles 16
REMUNE 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
IR-103 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
IR-502 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
IR-902 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
IR-777 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
IR-007 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
IR-1000 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
IR-1002 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
IR-2020 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
IR-222 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
IR-444 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
IR-555 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
IR-888 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
IR-999 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
IRE-101 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
IRR-102 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
IRS-103 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Immune Response BioPharma, Inc. - Pipeline Analysis 34
Immune Response BioPharma, Inc. - Pipeline Products by Target 34
Immune Response BioPharma, Inc. - Pipeline Products by Route of Administration 35
Immune Response BioPharma, Inc. - Pipeline Products by Molecule Type 36
Immune Response BioPharma, Inc. - Recent Pipeline Updates 37
Immune Response BioPharma, Inc. - Dormant Projects 39
Immune Response BioPharma, Inc. - Locations And Subsidiaries 40
Head Office 40
Appendix 41
Methodology 41
Coverage 41
Secondary Research 41
Primary Research 41
Expert Panel Validation 41
Contact Us 41
Disclaimer 42

List of Tables

Immune Response BioPharma, Inc., Key Information 6
Immune Response BioPharma, Inc., Key Facts 6
Immune Response BioPharma, Inc. - Pipeline by Indication, 2015 9
Immune Response BioPharma, Inc. - Pipeline by Stage of Development, 2015 10
Immune Response BioPharma, Inc. - Monotherapy Products in Pipeline, 2015 11
Immune Response BioPharma, Inc. - Pre-Registration, 2015 12
Immune Response BioPharma, Inc. - Phase II, 2015 13
Immune Response BioPharma, Inc. - Phase I, 2015 14
Immune Response BioPharma, Inc. - Preclinical, 2015 15
Immune Response BioPharma, Inc. - Pipeline by Target, 2015 34
Immune Response BioPharma, Inc. - Pipeline by Route of Administration, 2015 35
Immune Response BioPharma, Inc. - Pipeline by Molecule Type, 2015 36
Immune Response BioPharma, Inc. - Recent Pipeline Updates, 2015 37
Immune Response BioPharma, Inc. - Dormant Developmental Projects,2015 39